Advertisement
ORGO vs PRGO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORGO is a Hold and PRGO is a StrongBuy.
Momentum Indicator for ORGO turns negative, indicating new downward trend
ORGO saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 78 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ORGO turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ORGO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
ORGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.894) is normal, around the industry mean (10.407). P/E Ratio (-1.321) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.404) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ORGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for PRGO turns positive, indicating new upward trend
PRGO saw its Momentum Indicator move above the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 58 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PRGO just turned positive on October 12, 2026. Looking at past instances where PRGO's MACD turned positive, the stock continued to rise in 24 of 40 cases over the following month. The odds of a continued upward trend are 60%.
Following a +4.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRGO advanced for three days, in 179 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 120 of 204 cases where PRGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for PRGO moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 25 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
PRGO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.878) is normal, around the industry mean (10.407). P/E Ratio (-1.271) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (1.142) is also within normal values, averaging (2.152). Dividend Yield (0.073) settles around the average of (0.037) among similar stocks. P/S Ratio (0.454) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PRGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ORGO | PRGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 93 | 37 | |
P/E GROWTH RATING 1..100 | 97 | 89 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRGO's Valuation (7) in the Pharmaceuticals Other industry is in the same range as ORGO (38) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
PRGO's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ORGO (100) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
PRGO's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ORGO (98) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
PRGO's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (93) in the Financial Conglomerates industry. This means that PRGO’s stock grew somewhat faster than ORGO’s over the last 12 months.
PRGO's P/E Growth Rating (89) in the Pharmaceuticals Other industry is in the same range as ORGO (97) in the Financial Conglomerates industry. This means that PRGO’s stock grew similarly to ORGO’s over the last 12 months.
| ORGO | PRGO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 66% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 62% |
| Advances ODDS (%) | N/A | 7 days ago 64% |
| Declines ODDS (%) | 7 days ago 88% | 22 days ago 69% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORGO’s FA Score shows that 0 FA rating(s) are green while PRGO’s FA Score has 1 green FA rating(s).
- ORGO’s FA Score: 0 green, 5 red.
- PRGO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORGO’s TA Score shows that 3 TA indicator(s) are bullish while PRGO’s TA Score has 4 bullish TA indicator(s).
- ORGO’s TA Score: 3 bullish, 4 bearish.
- PRGO’s TA Score: 4 bullish, 4 bearish.
Price Growth
ORGO (@Pharmaceuticals: Generic) experienced а -13.04% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was -0.25% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
ORGO is expected to report earnings on Nov 05, 2026.
PRGO is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ORGO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIK could also see price increases.
| Ticker / NAME | Correlation To ORGO | 1D Price Change % | ||
|---|---|---|---|---|
| ORGO | 100% | +3.90% | ||
| ANIK - ORGO | 36% Loosely correlated | +2.38% | ||
| PRGO - ORGO | 31% Poorly correlated | +2.89% | ||
| ACET - ORGO | 29% Poorly correlated | -4.68% | ||
| IRWD - ORGO | 23% Poorly correlated | +0.56% | ||
| AMPH - ORGO | 23% Poorly correlated | -0.61% | ||
More | ||||
PRGO and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with SUPN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then SUPN could also see price increases.
| Ticker / NAME | Correlation To PRGO | 1D Price Change % | ||
|---|---|---|---|---|
| PRGO | 100% | +2.89% | ||
| SUPN - PRGO | 49% Loosely correlated | +2.09% | ||
| ELAN - PRGO | 37% Loosely correlated | +0.62% | ||
| EVO - PRGO | 35% Loosely correlated | -1.28% | ||
| PBH - PRGO | 35% Loosely correlated | +3.21% | ||
| ALVO - PRGO | 34% Loosely correlated | -6.63% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MYHC | 24.45 | 0.03 | +0.10% |
| State Street My2029 High Yield Corporate Bond ETF (MYHC) | |||
| AMUB | 21.93 | N/A | N/A |
| ETRACS Alerian MLP Index ETN Class B (AMUB) | |||
| MLPA | 53.79 | -0.23 | -0.43% |
| Global X MLP ETF (MLPA) | |||
| GJAN | 46.21 | -0.25 | -0.53% |
| FT Vest U.S. Equity Moderate Buffer ETF - Jan (GJAN) | |||
| XSPI | 49.00 | -0.82 | -1.64% |
| NEOS Boosted S&P 500 High Income ETF (XSPI) | |||